Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Yaroslav Dmytrenko
Yaroslav Dmytrenko

Biogen announces live webcast for Q3 2026 financial results: Can BIIB break above $254.45?

Biogen announces live webcast for Q3 2026 financial results: Can BIIB break above $254.45?
Biogen stock edges higher to $252.73

Biogen announced its third-quarter earnings and raised the lower end of its full-year earnings guidance. The stock edges higher on the day, trading at $252.73.

BIIB price prediction
24H 0.38%
$254.59
48H 0.51%
$254.91
7D 0.16%
$254.02
1M 11.53%
$282.85
3M 30.93%
$332.07
6M 35.32%
$343.19
12M 64.06%
$416.08
Detailed
Current price: $253.62 3.86 1.55%
Closed 10/30
Daily range 251.28 Arrow from to Icon 258.68
Weekly range 243.55 Arrow from to Icon 258.68
Loading...

Highlights

  • Biogen reported third-quarter revenue of $2.8 billion and raised the lower end of its full-year EPS guidance to $12.20 to $13.00.
  • 92 of 142 analysts rate Biogen stock a buy, with 4 recommending selling and JP Morgan giving a $300 target.
  • Biogen stock edges higher on the day, trading at $252.73.

Biogen announced it would host a live webcast for its Q3 2026 financial results at 8:30AM ET. The company reported total revenue of $2.8 billion for the quarter. It also raised the lower end of its full-year 2026 diluted EPS guidance to $12.20-13.00, according to Newsquawk.

Daily uptrend holds as RSI signals overbought conditions

The latest session showed an intraday range stretching from $248.46 to $253.98, much wider than the weekly average. Price remains supported by holding above its MA-20, MA-50, and MA-200, which keeps the daily structure bullish. The RSI reading of 72 is in overbought territory, indicating limited room for further upside. Immediate resistance comes in at the weekly high of $254.45.

Upside odds dominate as traders focus on $254.45 level

Traders should watch for a close above $254.45 to gauge whether buyers are willing to follow through. During the session, shares traded between $248.46 and $253.98, expanding well beyond typical intraday moves for the week. Even with a sustained move higher and a firm trend over the past week, the probability for further gains over the next five trading days is 78%, while the chance of a downside move is 22%, with an expected trading range of $246.28 to $259.17. A drop below $240.03 would signal that the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.

Previously it was reported that Biogen's strategic investments and acquisitions had established a broadly bullish technical outlook for the stock. The latest earnings surprise and guidance raise reinforce this constructive trend, with immediate focus on whether the stock can decisively break above the weekly resistance at $254.45.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

How German metalworkers’ strikes are testing Europe’s industrial strength
  • By Dmytro Kharkov
  • 49 min ago
How German metalworkers’ strikes are testing Europe’s industrial strength
Editors' Picks
DeFi for the select few: Why Hyperliquid is building restricted markets
  • By Pavlo Kot
  • Yesterday
DeFi for the select few: Why Hyperliquid is building restricted markets
Editors' Picks
Can Bitcoin make you a millionaire?
  • By Pavlo Kot
  • 31.10.2026
Can Bitcoin make you a millionaire?
Editors' Picks
All Editors' Top Picks

Latest Biogen News

Biogen New Ventures takes part in Series A funding for Estuary Biotherapeutics: Can BIIB break above $240.99?
  • By Mykhailo Ihnatenko
  • 16.10.2026
Biogen New Ventures takes part in Series A funding for Estuary Biotherapeutics: Can BIIB break above $240.99?
Companies
#Biogen
Biogen stock edges lower despite RayThera partnership
  • By Andreas Kristo
  • 07.08.2026
Biogen stock edges lower despite RayThera partnership
Companies
#Biogen
Biogen stock trades up toward $207.56 with buyers in control above MA-20 and Kijun support
  • By Ezequiel Gomes
  • 05.08.2026
Biogen stock trades up toward $207.56 with buyers in control above MA-20 and Kijun support
Companies
#Biogen
All Biogen News
  • Dmytro Kharkov
  • 49 min ago
How German metalworkers’ strikes are testing Europe’s industrial strength
  • Pavlo Kot
  • Yesterday
DeFi for the select few: Why Hyperliquid is building restricted markets
  • Pavlo Kot
  • 31.10.2026
Can Bitcoin make you a millionaire?
  • Olena Litvinenko
  • 30.10.2026
France's crypto market matures as regulation reshapes the industry
  • Dmytro Kharkov
  • 30.10.2026
SK Hynix’s rise reshapes the global chip industry and economy
  • Elena Nikulina
  • 53 min ago
Crypto and stablecoin transaction tax approved by slim margin, Gregory Raymond notes
  • Mikhail Vnuchkov
  • 53 min ago
Robert Peston: Questions raised on growth and debt reduction plans in budget discussion
  • Mykhailo Ihnatenko
  • 1 hour ago
Ethereum offers neutrality and censorship resistance, Joseph Lubin states
  • Yaroslav Dmytrenko
  • 1 hour ago
Securing the environment is key before Binance resumes, Yi He says
  • Eugene Komchuk
  • 1 hour ago
Mario Nawfal: U.S. healthcare spending rose to $5.3 trillion in 2024
Top News
  • Andrey Mastykin
  • 12 min ago
Anthropic taps Japanese investors ahead of major U.S. listing as AI financing expands
Anthropic taps Japanese investors ahead of major U.S. listing as AI financing expands
  • Olga Shendetskaya
  • 1 hour ago
Gulf states urge Washington to avoid new confrontation with Iran
Gulf states urge Washington to avoid new confrontation with Iran
  • Eugene Komchuk
  • 1 hour ago
Binance customers withdraw $5.8 billion in wake of hack
Binance customers withdraw $5.8 billion in wake of hack
  • Jose Antonio Gastelum
  • 21 hours ago
OPEC set to hold oil quotas as Middle East risks constrain supply
OPEC set to hold oil quotas as Middle East risks constrain supply
  • Ezequiel Gomes
  • 23 hours ago
Big Tech selloff drives investors back toward U.S. Treasuries
Big Tech selloff drives investors back toward U.S. Treasuries
Live News
  • Mykhailo Ihnatenko
  • Now
Ethereum price struggles above $2,300 despite $63M whale purchase
  • Andrey Mastykin
  • Now
Eurozone economy slows as France slips into recession fears
  • Anton Kharitonov
  • Now
EUR/USD recovery stalls near 1.1210 as dollar retains its fundamental advantage
  • Anastasiia Chabaniuk
  • Now
Binance launches stolen asset recovery and allocates $6.34 billion to cover losses
  • Mykhailo Ihnatenko
  • Now
AMD stock drops over 7% as Intel outlook hits semiconductor sentiment
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers